

VACCELERATE

The New European Vaccine Research Network

WHO WE ARE

- Clinical research network for the coordination & execution of COVID-19 vaccine trials
- Currently 214 clinical trial sites in 30 European countries
- Involved academic institutions: University Hospital Cologne as lead & 26 national partners in 16 EU & 5 EU-associated countries
- Funded by the European Commission with currently 12 Mio. €
- Part of the European Commission's activities in future pandemic preparedness, including the "HERA Incubator", in analogy to U.S. BARDA

OUR MISSION

- Serve as single-entry point for all stakeholders in COVID-19 vaccine development (pharma, academia, European Commission, EMA, ECDC, national health authorities and others) for phase 2 and 3 trials in Europe
- Address any research question of interest outside the big registration trials, such as vaccine efficacy in virus variants, trials in children, pregnant women, immunocompromised patients, trials on combination of different vaccines etc.

CURRENT ACTIVITIES

- Capacity mapping of new clinical trial sites & laboratories with standardised methods for harmonised vaccine trials
- Implementation of standardized educational measures, training & quality management for clinical trial sites
- Harmonisation of data acquisition across all network sites, thus facilitating open data exchange for valid data analysis
- Set-up of volunteer registries for vaccine trials for fast & efficient recruitment (>19,000 volunteers in Germany alone, expansion to more countries ongoing)

CONTACT & INFORMATION

Main primary contact through: info@vaccelerate.eu
<https://www.vaccelerate.eu/>
<https://www.euvap.eu/>
<https://www.vaccelerate.eu/volunteer-registry/index.html>
Twitter: @vaccelerate_eu